In vivo acute toxicity assessment of a novel quinoxalinone (6-nitro-2 (1H)-quinoxalinone) in Wistar rats

References

• Antoniotti, S., & Duñach, E. (2002). Direct and catalytic synthesis of quinoxaline derivatives from epoxides and ene-1, 2-diaminess. Tetrahedron Letters, 43, 3971–3973.10.1016/S0040-4039(02)00715-3
   Google Scholar
• Aparicio, D., Attanasi, O. A., Filippone, P., Ignacio, R., Lillini, S., Mantellini, F., … de los Santos, J. M. (2006). Straightforward access to pyrazines, piperazinones, and quinoxalines by reactions of 1,2-diaza-1,3-butadienes with 1,2-diamines under solution, solvent-free, or solid-phase conditions. The Journal of Organic Chemistry, 71, 5897–5905.10.1021/jo060450v
   Google Scholar
• Brown, D. J., Taylor, E. C., & Ellman, J. A. (2004). The chemistry of heterocyclic compounds. Hoboken, NJ: Wiley.
   Google Scholar
• Canadian Council on Animal Care (1993). Manual on the care and use of experimental animals. Ottawa, 1993, 232–256.
   Google Scholar
• Carta, A., Paglietti, G., Nikookar, M. E. R., Sanna, P., Sechi, L., & Zanetti, S. (2002). Novel substituted quinoxaline 1, 4-dioxides with in vitro antimycobacterial and anticandida activity, European Journal of Medicinal Chemistry, 37, 355–366.10.1016/S0223-5234(02)01346-6
   Google Scholar
• Chang, D. W., Ko, S. J., Kim, J. Y., Dai, L., & Baek, J. B. (2012). Multifunctional quinoxaline containing small molecules with multiple electron-donating moieties: Solvatochromic and optoelectronic properties. Synthetic Metals, 162, 1169–1176.
   Google Scholar
• Chesseman, G. W. H., & Cookson, R. F. (1979). The chemistry of heterocyclic compounds, condensed pyrazines (vol. 35). Hoboken, NJ: John Wiley & Sons, Inc.10.1002/SERIES1079
   Google Scholar
• Claude, A. (1988). Toxicological investigations for a new drug. In J. Giroud, G. Mathé, & G. Meyniel (Coordinators). Clinical pharmacology/therapeutic basics (2nd ed., pp. 3–14). Paris: French Scientific Expansion.
   Google Scholar
• Deepika, Y., Surendra, P., Sachin, N. K., & Shewta, S. (2011). Biological activity of quinoxaline derivatives. International Journal of Current Pharmaceutical Review and Research, 1, 33–46.
   Google Scholar
• El Adnani, Z., Mcharfi, M., Sfaira, M., Benjelloun, A. T., Benzakour, M., Ebn Touhami, M., Hammouti, B., & Taleb, M. (2012). Investigation of newly pyridazine derivatives as corrosion inhibitors in molar hydrochloric acid. Part III: Computational calculations. International Journal of Electrochemical Science, 7, 3982–3996.
   Google Scholar
• Hassan, S. Y., Khattab, S. N., Bekhit, A. A., & Amer, A. (2006). Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorganic and Medicinal Chemistry Letters, 16, 1753–1756.10.1016/j.bmcl.2005.11.088
   Google Scholar
• Hong, Y. S., Kim, H. M., Park, Y. T., & Kim, H. S. (2000). Heterocyclic compounds with sulfone functional groups (II): Synthesis of 1-arenesulfonyl-2-quinoxalinones. Bulletin of the Korean Chemical Society, 21, 133–136.
   Google Scholar
• Justin Thomas, K. R., Velusamy, M., Lin, J. T., Chuen, C. H., & Tao, Y. T. (2005). Chromophore-labeled quinoxaline derivatives as efficient electroluminescent materials. Chemistry of Materials, 17, 1860–1866.
   Google Scholar
• Kabanda, M. M., & Ebenso, E. E. (2012). Density functional theory and quantitative structure-activity relationship studies of some quinoxaline derivatives as potential corrosion inhibitors for copper in acidic medium. International Journal of Electrochemical Science, 7, 20.
   Google Scholar
• Kew, M. C. (2000). Serum aminotransferase concentration as evidence of hepatocellular damage. The Lancet, 355, 591–592.10.1016/S0140-6736(99)00219-6
   Google Scholar
• Kulkarni, N. V., Revankar, V. K., Kirasur, B. N., & Hugar, M. H. (2012). Transition metal complexes of thiosemicarbazones with quinoxaline hub: An emphasis on antidiabetic property. Medicinal Chemistry Research, 21, 8.
   Google Scholar
• Kunkuma, V., Bethala, L. A. P. D., Bhongiri, Y., Rachapudi, B. N. P., & Potharaju, S. S. P. (2011). An efficient synthesis of quinoxalines catalyzed by monoammonium salt of 12-tungstophosphoric acid. European Journal of Chemistry, 2, 495–498.10.5155/eurjchem.2.4.495-498.413
   Google Scholar
• Löscher, W., & Hönack, D. (1994). Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: Comparison with diazepam and interactions with flumazenil. British Journal of Pharmacology, 113, 1349–1357.10.1111/bph.1994.113.issue-4
   Google Scholar
• Mahesh, R., Devadoss, T., Pandey, D. K., Bhatt, S., & Yadav, S. K. (2010). Design, synthesis and structure–activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression. Bioorganic & Medicinal Chemistry Letters, 20, 6773–6776.10.1016/j.bmcl.2010.08.128
   Google Scholar
• Nakache, R., El Faydy, M., Berkiks, I., Ouichou, A., El Hessni, A., Lakhrissi, B., Benazzouz, B., & Mesfioui, A. (2015). Anti-anxiety- and antidepressant-like effects of the combination of 6-nitro-2(1h)-quinoxalinone and 2(1h)-quinoxalinone in wistar rats. World Journal of Pharmaceutical Research, 4, 281–295.
   Google Scholar
• Nakache, R., Lakhrissi, B., Mrabet, F. Z., Elhessni, A., Ouichou, A., Benazzouz, B., & Mesfioui, A. (2012). Synthesis and influence of two quinoxalinone derivatives on anxiety- and depressive-like responses in Wistar Rat. Neuroscience & Medicine, 3, 330–336. doi:10.4236/nm.2012.34039
   Google Scholar
• Nordholm, L., Sheardown, M., & Honoré, T. (1997). Clinical results with antagonists. In P. L. Herrling (Ed.), Excitatory amino acids (pp. 89–97). London: Academic Press.10.1016/B978-012546820-6/50010-4
   Google Scholar
• OCDE. (2000). Guidance document on the recognition, assessment and use of clinical signs as humane endpoints for experimental animals used in safety evaluation (No. 19). Environmental Health and Safety Monograph Series on Testing and Assessment.
   Google Scholar
• OCDE. (2001). Guidance document on acute oral toxicity (No. 24). Environmental Health and Safety Monograph Series on testing and assessment.
   Google Scholar
• Olayiwola, G., Obafemi, C. A., & Taiwo, F. O. (2007). Synthesis and neuropharmacological activity of some quinoxalinone derivatives. African Journal of Biotechnology, 6, 777–786.
   Google Scholar
• Sarges, R., Howard, H. R., Browne, R. G., Lebel, L. A., Seymour, P. A., & Koe, B. K. (1990). 4 Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. Journal of Medicinal Chemistry, 33, 2240–2254.10.1021/jm00170a031
   Google Scholar
• Sharma, G., Raisinghani, P., Abraham, I., Pardasani, R. T., & Mukherjee, T. (2009). Synthesis of quinoxaline quinones and regioselectivity in their Diels-Alder cycloadditions. Indian Journal of Chemistry, 48B, 1590–1596.
   Google Scholar
• Shi, D. Q., Dou, G. L., Ni, S. N., Shi, J. W., & Li, X. Y. (2008). An efficient synthesis of quinoxaline derivatives mediated by stannous chloride. Journal of Heterocyclic Chemistry, 45, 1797–1801.10.1002/jhet.v45:6
   Google Scholar
• Sirwal, I. A., Banday, K. A., Reshi, A. R., Bhat, M. A., & Wani, M. M. (2004). Estimation of Glomerular Filteration Rate (GFR). JK Science, 6, 121–123.
   Google Scholar
• Varano, F., Catarzi, D., Colotta, V., Cecchi, L., Filacchioni, G., Galli, A., & Costagli, C. (2001). Synthesis of a set of ethyl 1-carbamoyl-3-oxoquinoxaline-2-carboxylates and of their constrained analogue imidazo[1,5-a]quinoxaline-1,3,4-triones as glycine/NMDA receptor antagonists. European Journal of Medicinal Chemistry, 36, 203–209.10.1016/S0223-5234(00)01203-4
   Google Scholar